AI Article Synopsis

Article Abstract

The progress and problems in the Caribbean Amblyomma Program (CAP) are reviewed since its inception in 1995. During 1998, there were funding and administrative management problems. USDA resolved the acute funding crisis, and after three years of negotiation, the CAP has now secured an additional euro 1.5 million from the European Community. Changes in administration in 1998 included the withdrawal of IICA from the program, and the transition during the decentralization of administrative and financial management from FAO headquarters to the Regional Office for Latin America and the Caribbean, based in Chile. A general overview of technical progress and one case study, St. Kitts, is presented. One major concern that emerged during 2000 is that the elimination of the small remaining tropical bont tick (TBT) "hot spots" in both St. Kitts and St. Lucia remained elusive. Why is this so? Egrets? Alternative residual hosts? Or is it fatigue in both technical and administrative management functions? Of even greater concern is the finding of two, apparently new, foci in St. Croix (USVI) in the north and St. Vincent in the south. A critical overview of the program has identified one major remaining constraint-an appropriate management support function at both regional and, in some countries, at the national level. A proposal for a revised management strategy, coupled with the identification of a future strategy to succeed the CAP, namely a Caribbean Animal Resources Management (CARM) Program.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1749-6632.2002.tb04396.xDOI Listing

Publication Analysis

Top Keywords

tropical bont
8
bont tick
8
caribbean amblyomma
8
amblyomma program
8
administrative management
8
management
6
caribbean
5
program
5
eradication tropical
4
tick caribbean
4

Similar Publications

Botulinum neurotoxin, produced by the bacterium Clostridium botulinum, causes botulism, a severe, rapidly progressing, and potentially fatal condition. Swift detection of the toxin and timely administration of antitoxin antibodies are critical for effective treatment. The current standard for Botulinum toxin testing is the mouse lethality assay, but this method is time-consuming and requires live animals.

View Article and Find Full Text PDF

Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial.

Obstet Gynecol

February 2025

Children's Hospital Colorado, Aurora, Colorado; Vaccine Research and Development, Pfizer Inc, Pearl River, New York; the South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit and Wits Infectious Diseases and Oncology Research Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, and Famcru, Department of Paediatrics and Child Health, University of Stellenbosch, and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, SA-MRC Unit on Child and Adolescent Health, University of Cape Town, Cape Town, South Africa; Vaccines and Immunity Team, Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, the Gambia; Institute for International Health Charité, Universitätsmedizin, Berlin, Germany; Vaccine Research and Development, Pfizer Ltd, Marlow, United Kingdom; Instituto de Maternidad y Ginecología Nuestra Señora de Las Mercedes, San Miguel de Tucumán, and iTrials-Hospital Militar Central and iTrials, Buenos Aires, Argentina; Clinical Research Prime, Idaho Falls, Idaho; Boeson Research, Missoula, Montana; Meridian Clinical Research, Hastings, Nebraska; Asian Hospital and Medical Center, Manila, the Philippines; Department of Pediatrics, Spaarne Gasthuis, Haarlem and Hoofddorp, the Department of Pediatrics, Department of Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, and the ReSViNET Foundation, Zeist, the Netherlands; Meilahti Vaccine Research Center MeVac, Inflammation Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; National Taiwan University Hospital, Taipei, Taiwan; the Department of Obstetrics and Gynecology, Sendai City Hospital, Sendai, Japan; Institute of Biomedical Sciences, University of Chile School of Medicine, Santiago, Chile; University of Otago and New Zealand Clinical Research, Christchurch, New Zealand; CHU Sainte-Justine, Montreal, Quebec, Canada; Hospital Moinhos de Vento and Pontifícia Universidade Católica RGS, Porto Alegre, Brazil; the Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark; Arké SMO S.A. de C.V., Mexico City, Mexico; University of Western Australia School of Medicine, Vaccine Trials Group, Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, and Perth Children's Hospital, Nedlands, Western Australia, and Vaccine Clinical Research, Pfizer Inc, Sydney, Australia; and Worldwide Safety, Pfizer Srl, Milan, Italy.

Objective: To evaluate descriptive efficacy data, exploratory immunogenicity data, and safety follow-up through study completion from the global, phase 3 MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal vaccination trial of bivalent respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVpreF).

Methods: MATISSE was a phase 3, randomized, double-blinded, placebo-controlled trial. Healthy pregnant participants aged 49 years or younger at 24-36 weeks of gestation were randomized (1:1) to receive a single RSVpreF 120 micrograms or placebo dose.

View Article and Find Full Text PDF

The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access.

Lancet Infect Dis

December 2024

Department of Paediatric Infectious Disease & Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands. Electronic address:

Article Synopsis
  • RSV is a significant cause of infant mortality and poses health risks for older adults, prompting the development of various vaccines and treatments, including a protein-based maternal vaccine and monoclonal antibodies (mAb) specifically for infants.* -
  • High-income countries have seen public health benefits from using nirsevimab, and several vaccines for older adults have also been approved, with ongoing clinical trials for multiple vaccine types targeting different age groups.* -
  • There's a need to address disparities in vaccine access, especially in low- and middle-income countries, with plans to advance RSV vaccination efforts globally in the near future.*
View Article and Find Full Text PDF

Socioeconomic inequalities in the exposome have been found to be complex and highly context-specific, but studies have not been conducted in large population-wide cohorts from multiple countries. This study aims to examine the external exposome, encompassing individual and environmental factors influencing health over the life course, and to perform dimension reduction to derive interpretable characterization of the external exposome for multicountry epidemiological studies. Analyzing data from over 25 million individuals across seven European countries including 12 administrative and traditional cohorts, we utilized domain-specific principal component analysis (PCA) to define the external exposome, focusing on air pollution, the built environment, and air temperature.

View Article and Find Full Text PDF

Growing evidence suggests that extreme heat events affect both pregnant women and their infants, but few studies are available from sub-Saharan Africa. Using data from 138,015 singleton births in 16 hospitals in Benin, Malawi, Tanzania and Uganda, we investigated the association between extreme heat and early perinatal deaths, including antepartum and intrapartum stillbirths, and deaths within 24 h after birth using a time-stratified case-crossover design. We observed an association between an increase from the 75th to the 99th percentile in mean temperature 1 week (lag 0-6 d) before childbirth and perinatal mortality (odds ratio (OR) = 1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!